US trial of noninvasive ALS device gets green light to enroll patients
A clinical trial that will test a noninvasive, nerve-modulating device called MyoRegulator — designed to slow disease progression in…
Articles by Andrea Lobo, PhD
Neuropeutics partners to advance potential disease-modifying therapy
Neuropeutics has partnered with LifeArc to advance work on a small molecule therapy against TDP-43 clumping…
iPSC-derived microglia may help advance ALS research, therapies
Ncardia has launched a stem cell-derived model of human microglia to advance research into neurodegenerative disorders such as amyotrophic…
ROCK inhibitor Bravyl may reduce spread of TDP-43 clumps in ALS
Bravyl (oral fasudil), an experimental therapy Woolsey Pharmaceuticals is developing for amyotrophic lateral sclerosis (ALS), significantly reduced the…
Kadimastem, NLS merge to advance ALS therapy AstroRx, other drugs
Kadimastem, the developer of the experimental amyotrophic lateral sclerosis (ALS) therapy AstroRx, is merging with NLS Pharmaceutics…
Woolsey gets 3 US patents covering ROCK inhibitor Bravyl
Woolsey Pharmaceuticals has received three new U.S. patents covering innovations related to Bravyl (oral fasudil), its investigational amyotrophic lateral…
Texas Children’s investigator wins $2.4M grant for ALS research
A Texas Children’s Hospital investigator has received a $2.4 million grant for a study that seeks to understand whether mechanisms…
Avextra to launch Phase 2 trial of cannabis-based medicine in Italy
Avextra is set to launch a Phase 2 trial in Italy to test a cannabis-based oral medication for the…
PrimeC, potential ALS treatment, given US patent for its formulation
Neurosense Therapeutics announced that it has received a U.S. patent covering the formulation of PrimeC, its…
Mabylon gets funding to advance human-derived antibodies for ALS
The Swiss biotechnology company Mabylon has received two research grants from Target ALS and the ALS Association…